Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity
For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for maintaining disease control over 24 weeks, according to a study published online Oct. 6 in Arthritis & Rheumatology.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Congo's confirmed Ebola cases exceed 9,000 as containment efforts falter
United Kingdom
-
Vaccine redesign may separate Zika protection from risk of worsening dengue
United Kingdom
-
Stress during pregnancy may change placental signals linked to fetal brain development
United Kingdom
-
Australian data reveal sharp rise in recorded violence against children over past decade
United Kingdom
-
Pancreatic cancer cells continuously reshape DNA to evade treatment
United Kingdom
-
Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers
United Kingdom
-
WHO experts recommend HPV shot for girls aged 4–8
United Kingdom
-
Protein clues may help explain heart disease risk that persists despite lower LDL cholesterol
United Kingdom